Project Grant R01CA304255
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $574K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- The National Cancer Institute awarded the University of Arizona $544,929 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of estrogen receptor in regulating breast cancer cell invasion. The research examines how matrix stiffness and estrogen act as critical regulators of estrogen receptor-positive (ER+) breast cancer invasion in the tumor microenvironment. The work focuses on mechanohormonal conditioning—the interplay between a tumor cell's...
- The National Cancer Institute awarded the University of Arizona $545,195 under the Cancer Biology Research program (CFDA 93.396) on July 10, 2026, to interrogate niche-specific nuclear and extra-nuclear estrogen receptor-alpha (ER) signaling to prevent ER+ breast cancer progression in bone. The project will identify tumor versus bone niche-specific and ER pathway-specific, tumor-promoting effects of ER signaling using a human breast cancer bone metastasis model combined with pharmacologic and...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $426,828 on May 4, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing R21CA313397). The award funds research into JUMONJI KDM5 histone demethylase enzymes and their role in mediating resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. The project tests sensitivity of CDK inhibitor-resistant cell...
- The National Cancer Institute awarded $668,878 to the University of Texas at Austin on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting CD44 variant 9 for advanced and treatment-resistant breast cancer. The research addresses the clinical need for new therapeutic options for patients with triple-negative and heavily treated hormone receptor-positive metastatic breast cancer who have relapsed or progressed after current...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $150,898 to the University of Texas at Austin on June 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and validate gene activators of cancer cell-cell fusion that contribute to chromosomal instability and tumor evolution in triple negative breast cancer. The project will perform a pooled CRISPR activation screen in triple negative breast cancer cells to discover genes...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $389,828 on September 15, 2025, under the Cancer Research Manpower program (CFDA 93.398) to model enhancer hijacking in cancer through genome engineering and single-cell sequencing. The award funds research led by Dr. Xu to investigate how structural variants rewire enhancer-promoter communication and drive oncogene activation in rearranged human genomes. The research employs CRISPR/CAS9 genome...
- The National Cancer Institute awarded the Texas A&M Engineering Experiment Station $453,464 on August 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how extracellular matrix stiffness governs clonal selection and evolution in tumor cells, with particular focus on heritable traits linked to metastasis fitness. The research examines how genetically heterogeneous tumor cell populations adapt to varying mechanical environments encountered during metastasis and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Cancer Institute awarded Texas A&M Engineering Experiment Station $471,793 on July 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate the role of nuclear architecture in regulating YAP/TAZ transcriptional programs in head and neck squamous cell carcinoma. The research addresses a gap in understanding how YAP1/TAZ activation triggers opposing cellular outcomes—tumor proliferation or epithelial-to-mesenchymal transition (EMT)—in...